Cancers, Free Full-Text

The field of cancer research is famous for its incremental steps in improving therapy. The consistent but slow rate of improvement is greatly due to its meticulous use of consistent cancer biology models. However, as we enter an era of increasingly personalized cancer care, including chemo and radiotherapy, our cancer models must be equally able to be applied to all individuals. Patient-derived organoid (PDO) and organ-in-chip (OIC) models based on the micro-physiological bioengineered platform have already been considered key components for preclinical and translational studies. Accounting for patient variability is one of the greatest challenges in the crossover from preclinical development to clinical trials and patient derived organoids may offer a steppingstone between the two. In this review, we highlight how incorporating PDO’s and OIC’s into the development of cancer therapy promises to increase the efficiency of our therapeutics.

Cancers, Free Full-Text

Remission, cancer-free, no evidence of disease: What's the

Cancer

Cancer-Free, Third Edition by Bill Henderson - Audiobook

Testicular Cancer: Symptoms, Signs, Causes & Treatment

Cancer Anniversary

Cancer-Free, Third Edition by Bill Henderson - Audiobook

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and

PDF) Combination of tumor markers predicts progression and

Prostate Cancer: Symptoms, Causes & Treatment

Know the signs of cancer to catch it early

Cancer & Oncology Nursing NCLEX Practice Quiz (170 Questions

PDF) Treatment outcome with low-dose-rate interstitial

Hallmarks of Cancer: The Next Generation: Cell

Celltracker Zip Get File - Colaboratory